Tirzepatide 5 mg showed an average weight loss of more than 5% of body weight at the median time of 16 weeks, while 10 and 15 mg took 12.4 weeks to show significant weight changes and glycemic control
10.1038/s41598-024-60159-7 Sci Rep
CAR-T Therapy Chimeric antigen receptor (CAR) T-cell therapy refers to an immunotherapeutic approach aimed at harnessing the anti-cancer potential of T cells
Results may vary based on individual factors such as genetics, health status, and lifestyle.
Expression of D3 was increased in the PBMC of hypertensive individuals (Ricci et al., 1997) and treating rats with the D3 agonist 7-OH-DPAT enhanced kidney function, which was blocked by pretreatment with a D3 specific antagonist (U-99194A) but not with the D2-like antagonist sulpiride (Luippold et al., 1998)
The scientists thought they had made a mistake